Edition:
India

Aethlon Medical Inc (AEMD.OQ)

AEMD.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
19 Jan 2018
Change (% chg)

$-0.01 (-0.71%)
Prev Close
$1.40
Open
$1.43
Day's High
$1.43
Day's Low
$1.36
Volume
48,232
Avg. Vol
124,593
52-wk High
$5.17
52-wk Low
$0.80

Select another date:

Thu, Jan 18 2018

BRIEF-Aethlon Medical Says Granted U.S. Patent That Broadens Protection For The Aethlon Hemopurifier

* AETHLON MEDICAL ANNOUNCES ALLOWANCE OF U.S. PATENT THAT BROADENS PROTECTION FOR THE AETHLON HEMOPURIFIER® TO TREAT VIRAL INFECTIONS Source text for Eikon: Further company coverage:

BRIEF-Sabrina Johnson Joins Aethlon Medical's Board Of Directors

* SABRINA MARTUCCI JOHNSON JOINS AETHLON MEDICAL'S BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical Names Dr. Charles J. Fisher Chairman Of The Board

* AETHLON MEDICAL NAMES DR. CHARLES J. FISHER CHAIRMAN OF THE BOARD Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical announces second quarter results

* Aethlon Medical announces fiscal 2018 second quarter results

BRIEF-AETHLON MEDICAL ANNOUNCES PRODUCTION COLLABORATION WITH IBIO INC

* AETHLON MEDICAL ANNOUNCES LARGE-SCALE PRODUCTION COLLABORATION

BRIEF-IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

* IBIO ANNOUNCES MANUFACTURING COLLABORATION WITH AETHLON MEDICAL

BRIEF-Intracoastal Capital reports 5.7 pct passive stake in Aethlon Medical

* Intracoastal Capital LLC reports 5.7 percent passive stake in Aethlon Medical Inc as of Oct 2 - SEC filing‍​ Source : (http://bit.ly/2ybZng4) Further company coverage:

BRIEF-Aethlon Medical Receives expedited access pathway designation from FDA

* Aethlon Medical receives expedited access pathway designation from FDA to accelerate U.S. access to the hemopurifier as a treatment for life-threatening viruses Source text for Eikon: Further company coverage:

BRIEF-Aethlon Medical received formal receipt from FDA for expedited access pathway program submission ‍​

* On Aug 14, co received formal receipt from the U.S. FDA for expedited access pathway program submission ‍​

BRIEF-Aethlon Medical reports Q1 loss per share $0.21

* Aethlon Medical announces fiscal 2018 first quarter results

Select another date: